Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Kelewan schreef op 4 september 2019 09:33 :
[...]
Ja, eerst op 8,90, laatste op 5,78. Zo van, ergens komt de ommekeer wel, toch blij dat dat gebeurt voor je moet bijkopen tot je een belang moet melden ;).
Als ik een belang zou moeten melden zou ik dat helemaal niet erg vinden :-)
Pharnext and Galapagos successfully achieved their research and development collaboration PARIS, France, 8:00 am, September 9, 2019 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, today announced the successful completion of its research and development collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a late-stage clinical biotechnology company specialized in the discovery and development of small molecule medicines with novel mechanisms of action. The collaboration aims to generate a new drug development pipeline in several therapeutic areas for Galapagos, including immunoinflammatory disorders. Namely, the collaboration was focused on the identification of: • Additional therapeutic indications for Galapagos’ clinical drug candidates, • Novel candidates for combinations with Galapagos’ current portfolio of drug candidates, and • New therapeutic targets in indications pre-defined by Galapagos. Together, Pharnext and Galapagos have met their objectives. Leveraging its innovative PLEOTHERAPYTM platform, Pharnext successfully identified additional therapeutic indications for Galapagos’ candidate drugs. Combining Galapagos’ expertise in holistic pharmaceutical development with Pharnext’s cutting-edge approach, several of these new indications were further prioritized for experimental validation studies in animal models, in which Galapagos’ candidate drugs demonstrated efficacy. Pharnext’s PLEOTHERAPYTM platform also identified multiple approved drugs to combine with Galapagos’ candidate drugs in order to create a more potent effect in these selected indications. Some combinations of Galapagos’ candidate drugs with Pharnext’s identified drugs have already shown a superior effect in relevant animal models. Finally, Pharnext’s PLEOTHERAPYTM platform identified new targets in therapeutic indications that Galapagos had prioritized initially, supporting Galapagos’ research and development activities in these indications. “These results reaffirm the robustness of Pharnext’s development of combination drugs and validate its application to potentially any therapeutic area. Pharnext’s innovative approach bolsters the disease treatment path,” said Professor Daniel Cohen, MD, PhD, Co-Founder and Chief Executive Officer of Pharnext. “We are proud to collaborate with Galapagos to generate new treatment options for patients.” “We want to thank Pharnext for the rewarding collaboration, which has led to the identification of interesting novel combinations that are now in advanced preclinical testing,” said Piet Wigerinck, PhD, Chief Scientific Officer of Galapagos. This collaboration aims to expand the market of these novel combinations to new indications. Generating new patents should increase the value of these new compounds.
Pharnext is dus overbodig geworden voor Galapagos.
Dat denk ik niet. Als je dat er uit opmaakt, dan zou ik het bericht en de eerdere berichten maar nog een keer lezen. Er staat dat Pharnext samen met Galapagos op meerdere gebieden vooruitgang heeft geboekt. In het persbericht bij aanvang wordt o.a. Onno van de Stolpe geciteerd en daarbij staat ook dat het intellectuele eigendom een gezamenlijk eigendom is. Onno van de Stolpe, Chief Executive Officer van Galapagos voegde eraan toe: “Pharnext heeft al veelbelovende klinische resultaten verkregen met zijn geavanceerde technologie, wat ons heeft aangemoedigd om samen te werken. We zijn er erg blij mee samen te werken met Pharnext en profiteren van Pharnext's expertise in het ontcijferen van de moleculaire netwerken van ziekten. We hopen dat dit de R & D-mogelijkheden van Galapagos zal versterken om op een zeer efficiënte en moderne manier nieuwe therapeutische benaderingen te genereren. "Intellectuele eigendom met betrekking tot synergetische geneesmiddelencombinaties gegenereerd door de R & D-samenwerking zal gezamenlijk eigendom zijn van Pharnext en Galapagos.
ReBa schreef op 9 september 2019 10:31 :
Dat denk ik niet. Als je dat er uit opmaakt, dan zou ik het bericht en de eerdere berichten maar nog een keer lezen.
Er staat dat Pharnext samen met Galapagos op meerdere gebieden vooruitgang heeft geboekt.
In het persbericht bij aanvang wordt o.a. Onno van de Stolpe geciteerd en daarbij staat ook dat het intellectuele eigendom een gezamenlijk eigendom is.
Onno van de Stolpe, Chief Executive Officer van Galapagos voegde eraan toe: “Pharnext heeft al veelbelovende klinische resultaten verkregen met zijn geavanceerde technologie, wat ons heeft aangemoedigd om samen te werken. We zijn er erg blij mee samen te werken met Pharnext en profiteren van Pharnext's expertise in het ontcijferen van de moleculaire netwerken van ziekten.
We hopen dat dit de R & D-mogelijkheden van Galapagos zal versterken om op een zeer efficiënte en moderne manier nieuwe therapeutische benaderingen te genereren. "
Intellectuele eigendom met betrekking tot synergetische geneesmiddelencombinaties gegenereerd door de R & D-samenwerking zal gezamenlijk eigendom zijn van Pharnext en Galapagos. Helaas levert dat niks op in de komende 10 à 20 jaar.
Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A) • Results suggestsustained safety and efficacy of PXT3003 in CMT1A patients after 25 months of total trial time (Phase 3 trial + open-label extension study) • CMT1A patients showed improvement or stabilization of disease as measured by the Overall Neuropathy Limitations Scale during the open-label Phase 3 extension study Conference call in English today at 10:30 p.m. CET (4:30 p.m. ET) Conference call in French on Tuesday January 7 at 10:00 a.m. CET (4:00 a.m. ET) PARIS, France, 07:00 p.m., January 6, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomics data and artificial intelligence, today announced encouraging data from the open-label Phase 3 extension study of PXT3003 in patients with Charcot-Marie-Tooth Disease Type 1A (CMT1A). Data from 185 patients in the 9-month PLEO-CMT open-label extension study (PLEO-CMT-FU) were consistent with prior positive safety and tolerability results in the 15-month, double-blind Phase 3 study (PLEO-CMT). Highlights from a preliminary efficacy analysis1 of the open-label PLEO-CMT-FU study include: • Patients improved on the Overall Neuropathy Limitation Scale (ONLS) across all dose cohorts during the extension study as compared to the ONLS decline seen in the placebo group. • Patients treated with PXT3003 since the start of the Phase 3 program showed ONLS improvement or remained stable at the end of the PLEO-CMT-FU extension study as compared to the ONLS at the beginning of the PLEO-CMT study. • Patients with a decline in ONLS during their treatment interruption improved upon resuming treatment. “These data further reinforce our confidence in the safety and efficacy signals from the previous clinical studies,” said Daniel Cohen, M.D., Ph.D., co-founder and Chief Executive Officer of Pharnext. “We look forward to continuing our discussions with the U.S. Food and Drug Administration (FDA) and expect to align on the design of an additional pivotal Phase 3 trial in the first half of 2020, with the goal of initiating the study as soon as possible.” “Patients with CMT1A have no pharmacological treatment options for their chronic, progressive hereditary disease,” said Prof. Dr. med. Maggie C. Walter, M.A., Associate Professor of Neurology, Friedrich-BaurInstitute, Dept. of Neurology, Ludwig-Maximilians-University of Munich, Germany. “Although these data were generated from an open-labelstudy, the data seem to support the efficacy signal observed in the primary Phase 3 trial and suggest potential sustained efficacy over the course of two years.” Prof. Florian P. Thomas, M.D., M.A., Ph.D., M.S., Founding Chair & Professor, Department of Neurology, Hackensack Meridian School of Medicine, Hackensack, NJ, USA, said: “These results provide further argument that PXT3003 could potentially stabilize and even improve neurological function in patients with CMT1A. I am excited by these results and the potential for PXT3003 to serve as a novel and safe therapeutic approach for CMT1A patients.”www.pharnext.com/images/2020.01.06_PX...
Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19, Using its Pleotherapy™ Platform • A novel strategy to rapidly reposition drugs using existing COVID-19 clinical data • Methods, findings and proposals from Pharnext are available at Preprints.org (https://www.preprints.org/manuscript/202003.0302/v1) and awaiting peer review PARIS, France, 7:30am, March 23, 2020 (CET) – Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the identification of 97 frequently prescribed drugs as potential candidates to be repositioned for treating COVID-19 through the use of its Pleotherapy™ platform. In a pandemic emergency situation, the repurposing of already-known drugs is a method of choice prior to vaccine development. Various drug repositioning efforts are ongoing worldwide. However, the understanding of COVID-19, a disease that emerged less than four months ago, is highly limited. To respond to the urgency, especially as it may take up to a year before a vaccine is available to patients, Pharnext applied an original strategy based on its experience in complex disease mechanisms and bioinformatics methods in order to find drugs to modify the disease more immediately. Once a virus enters human cells, it utilizes the cellular machinery to its advantage, allowing the virus to proliferate within the human host. Pharnext’sstrategy was to evaluate which part of this machinery is affected by coronaviruses (e.g., COVID-19, SARS, MERS). This allowed the Company to identify already approved drugs for common diseases, which can also potentially impair the COVID-19-related viral process. In total, Pharnext identified 97 candidate drugs, most of which are not known to have antiviral activities. In addition, four of the drugs Pharnext identified using its methodology are already undergoing clinical trials for COVID-19, including chloroquine. A large group of the identified repositioning candidate drugs were originally developed and used for frequent medical conditions such as type 2 diabetes and hypertension. It happens that the individuals suffering from these diseases have some of the highest risks to evolve towards severe forms of COVID-19. This suggests, besides multiple potential reasons linking these pathologies and an outcome of COVID-19 infection, a biological link between these common diseases, sensitivity to COVID-19 and the drugs Pharnext hasidentified. Pharnext’s strategy of focusing on already approved drugs for common diseases as repositioning candidates (e.g., statins, anti-diabetic and anti-hypertensive drugs) results in two significant advantages: 1. Quickly prioritizes the best candidates by comparing COVID-19 evolution among patients taking these drugs vs. patients not taking these drugs, through big data analysis of medical records(“real- world evidence” testing), to rapidly launch launch further confirmatory studies. 2. Provide to the population: The rapid spread of the COVID-19 virus calls for a rapid response. Once proven effective, the top candidates could be made immediately available as they are already produced to treat common diseases. “Pharnext is dedicated to identifying potential drugs that may be repurposed to treat COVID-19,” said Daniel Cohen, M.D., Ph.D., co-founder and Chief Executive Officer of Pharnext. Groet, poil
which can be applied to any disease, Pharnext has conceived a method enabling a rapid drug repositioning to fight COVID-19. A coordinated international effort is urgently needed to mutualize i) comprehensive COVID-19 patient data and ii) confined facilities suited for significant experimental testing. For the sake of patients and our communities, we hope that the biopharma community and health regulatory agencies worldwide can work together to find a way for ultra-fast approval tracks for these and other therapies.” Candidate drugs proposed by Pharnext need to be further tested for confirmation, as mono- or polytherapy, following two parallel processesfor an accelerated preclinical evaluation and clinical development: 1)standard preclinical disease models and 2) “real-world evidence” testing, whereby big data from medical records are used to compare COVID-19 patients, who are already taking these candidate drugs. 1 Hydroxychloroquine, Chloroquine and Azythromicine have generated encouraging results in clinical trials, which have also been identified by Pharnext’s approach. Pharnext is currently evaluating various options to validate its initial findings as well as to further advance the work towards a treatment for COVID-19 through various collaborations.
Pharnext SA 3,78 0,89 30,80 % 09:14:30 Je hebt van die dagen.... Succes, poil
Pharnext SA 4,05 1,16 40,14 % Gaat snel!! Wordt een 100% dag Groet, poil
overnamekandidaat galapagos?
Pharnext SA 4,30 0,60 16,22 % 09:15:44 mobile.twitter.com/pharnext Nieuws! Succes, poil
Pharnext SA 4,55 0,85 22,97 % 09:20:07 Terug naar de 10 euro Groet, poil
Pharnext SA 4,62 0,92 24,86 % 10:11:33 Gaat richting de 5! Succes, poil
Pharnext SA 4,68 0,98 26,49 % 11:07:29 Dit gaat de goede kant op. Groet, poil
Ben benieuwd welk nieuws er aan gebonden is, ik denk dat dit gelinkt is aan hun persbericht over Covid-19 maar een overname zou ook altijd mooi zijn
al grote stijging, wachten op correctie voor aankoop?
Vraagje aan de kenners: wat kunnen we verwachten van het komende koersverkoop? Gezien waar de koers een paar maanden stond, zou het nog wat omhoog kunnen?
We need a Big Data effort to find a COVID-19 cure, says pioneering geneticist Famed French researcher Daniel Cohen, head of drug developer Pharnext, has a short list of 97 drugs that have been through some clinical testing that could play a role in a vaccine for COVID-19. To move things forward, the entire world needs to get together and share medical data on COVID-19 patients so the clues can be systematically studied. "I'm an optimist," says Daniel Cohen, a legendary French scientist, "If we can make this combined, coordinated effort, not just our laboratory, but all scientists working, worldwide, then, yes, I'm optimistic we can find a solution." From cancelled conferences to disrupted supply chains, not a corner of the global economy is immune to the spread of COVID-19. Cohen was talking about patients with COVID-19, the disease that results from the SARS-CoV2 virus, a disease that has engulfed the world's energy and attention. Cohen, 69, inaugurated the era of "Big Data" in the life sciences at the end of the 1980s, leading the effort then that produced the first "map" of the human genome. As with the human genome project, where world leaders joined with scientists to generate funds for laboratories that shared information, Cohen thinks the world needs to share patient data from COVID-19 on a massive scale, including symptoms, medical history, and drugs the patients are on. "We must have a coordinated effort to mutualize COVID-19 medical records, including records of all the medications being given to patients," said Cohen, "to analyze, with artificial intelligence tools, the influence, positive or negative, of their conditions, and their drugs, on this disease." Cohen spoke to ZDNet by phone on Sunday from Paris, where he is chief executive of development-stage drug maker Pharnext. The context was Cohen's announcement Monday that his Pharnext team has come up with 97 drugs that have been through various stages of clinical testing, that might play a role in an eventual vaccine for COVID-19. "Might" is the operative word. There is substantial complexity in the operation of the disease. It is widely known that primarily, but not exclusively, those dying are those who are older and who have "co-morbidities," pre-existing conditions that seem to become aggravated by the illness. The most prominent co-morbidities include hypertension, diabetes, cerebrovascular and cardiovascular diseases. There's a mystery as to why those conditions seem to make patients more susceptible. Is there an underlying "confounder," asks Cohen, a condition that produces both hypertension, say, and susceptibility to the virus. "Let's keep in mind that there are multiple potential other reasons for this comorbidity," says Cohen. "Organs from aged patients with diabetes or hypertension are often already damaged, therefore, COVID-19 might simply accelerate that degradation."
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee